HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Stern, L. M. Articles by Goldblatt, E. Search for Related Content PubMed PubMed Citation Articles by Stern, L. M. Articles by Goldblatt, E.

The progression of Duchenne muscular dystrophy

Clinical trial of allopurinol therapy

From the Regency Park Centre for Physically Handicapped Children (Dr. Stem), the Adelaide Children's Hospital (Drs. Fewings, Cooper, and Goldblatt), the South Australian Institute of Technology (Dr. Bretag), and the CSIRO Division of Human Nutrition (Drs. Ballard and Tomas), Adelaide, South Australia.

Address correspondence and reprint requests to Dr. Stem, Regency Park Centre for Physically Handicapped Children, Days Road, Regency Park, South Australia 5010, Australia.

A 12-month clinical study of Duchenne muscular dystrophy was carried out during a double-blind trial of allopurinol therapy. The disease was monitored by assessment of muscle power and function, pulmonary function tests, and electrocardiography. Biochemical assessments were made of plasma creatine kinase, pyruvate kinase, uric acid, and urinary excretion of 3-methylhistidine and creatinine. Allopurinol did not alter the progression of the disease.

This study was supported by a grant from the Channel 10 Children's Medical Research Foundation of South Australia.

Accepted for publication June 16, 1980.